Matt Hewitt
Stock Analyst at Craig-Hallum
(2.67)
# 2,143
Out of 4,981 analysts
40
Total ratings
54.05%
Success rate
3.48%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $14.68 | +145.23% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $8.30 | +44.58% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $3.14 | +91.08% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.80 | +24.03% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $32.26 | +98.39% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.37 | +629.93% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $18.46 | +62.51% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.45 | +382.76% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $113.74 | +75.84% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.61 | +521.12% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.67 | +291.13% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.71 | +23,291.81% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $14.68
Upside: +145.23%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $8.30
Upside: +44.58%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $3.14
Upside: +91.08%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.80
Upside: +24.03%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $32.26
Upside: +98.39%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.37
Upside: +629.93%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $18.46
Upside: +62.51%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.45
Upside: +382.76%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $113.74
Upside: +75.84%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.67
Upside: +291.13%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.71
Upside: +23,291.81%